|Daily Range||$34.20 - $34.79|
|52-Week Range||$33.23 - $38.71|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||892,668|
|Current FY EPS||$1.95|
News & Commentary
ImmunoGen shares lose half their value following an update on a key breast cancer drug trial. Find out whether today's swoon could mark a buying opportunity.
Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.
Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.
This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.
This 3D bioprinting company finally has a product on the market.
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.